<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23202" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Secondary Hyperparathyroidism</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Muppidi</surname>
            <given-names>Vijayadershan</given-names>
          </name>
          <aff>Indiana University health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Meegada</surname>
            <given-names>Sreenath R.</given-names>
          </name>
          <aff>University OF Texas Health Sciences Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rehman</surname>
            <given-names>Anis</given-names>
          </name>
          <aff>District Endocrine/Sentara Northern Virginia Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vijayadershan Muppidi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sreenath Meegada declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anis Rehman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23202.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hyperparathyroidism secondary to chronic renal failure is a condition characterized by inappropriate secretion of parathyroid hormone (PTH), secondary to a phosphocalcic metabolic disorder. Surgical management represents the only radical treatment of the disease and its indications are well established. This activity reviews the role of the interprofessional team in the diagnosis and treatment of this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications of surgery in case of secondary hyperparathyroidism.</p></list-item><list-item><p>Outline the appropriate evaluation of secondary hyperparathyroidism.</p></list-item><list-item><p>Review the management options available for secondary hyperparathyroidism.</p></list-item><list-item><p>Describe interprofessional team strategies to improve care coordination for secondary hyperparathyroidism.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23202&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23202">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23202.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Parathyroid hormone (PTH) is secreted by parathyroid glands and plays a role in calcium and skeletal metabolism.<xref ref-type="bibr" rid="article-23202.r1">[1]</xref>&#x000a0;Important triggers for PTH secretion are hypocalcemia and hyperphosphatemia.<xref ref-type="bibr" rid="article-23202.r2">[2]</xref>&#x000a0;On the other hand, the secretion of PTH is reduced by 1,25 (OH)(2) vitamin D(3).<xref ref-type="bibr" rid="article-23202.r2">[2]</xref>&#x000a0;Secondary hyperparathyroidism (SHPT) is an increased secretion of PTH due to parathyroid hyperplasia caused by triggers such as hypocalcemia, hyperphosphatemia, or decreased active vitamin D.<xref ref-type="bibr" rid="article-23202.r2">[2]</xref>&#x000a0;The&#x000a0;increased PTH secretion, in turn, causes increased calcium in the blood by acting on bones, intestines, and kidneys.<xref ref-type="bibr" rid="article-23202.r2">[2]</xref>&#x000a0;</p>
        <p>Prolonged SHPT is often associated with disturbances of bone turnover, as well as visceral and vascular calcifications, which are responsible for cardiovascular morbidity and mortality.<xref ref-type="bibr" rid="article-23202.r3">[3]</xref></p>
        <p>Despite improvements in medical treatment, surgical treatment of SHPT&#x000a0;is often necessary, especially in refractory cases.<xref ref-type="bibr" rid="article-23202.r4">[4]</xref>&#x000a0;Renal transplantation is a therapeutic alternative but is frequently followed by the persistence of hyperparathyroidism.<xref ref-type="bibr" rid="article-23202.r5">[5]</xref></p>
      </sec>
      <sec id="article-23202.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Secondary hyperparathyroidism is commonly associated with vitamin D deficiency and chronic kidney disease (CKD).<xref ref-type="bibr" rid="article-23202.r6">[6]</xref>&#x000a0;The kidney cannot convert vitamin D into the physiologically active 1,25-cholecalciferol.<xref ref-type="bibr" rid="article-23202.r7">[7]</xref>&#x000a0;Reduced intestinal absorption of calcium resulting in a low serum calcium and elevated phosphate due to&#x000a0;kidney's failure to excrete phosphate increases secretion of parathyroid hormone. Prolonged stimulation results in parathyroid hyperplasia.<xref ref-type="bibr" rid="article-23202.r7">[7]</xref>&#x000a0;SHPT also occurs in vitamin D-deficient rickets, malabsorption, and pseudohypoparathyroidism.<xref ref-type="bibr" rid="article-23202.r7">[7]</xref></p>
      </sec>
      <sec id="article-23202.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The most common causes of secondary hyperparathyroidism are vitamin D deficiency and chronic kidney disease.<xref ref-type="bibr" rid="article-23202.r6">[6]</xref>&#x000a0;About 50% of the world population is affected by vitamin D insufficiency.<xref ref-type="bibr" rid="article-23202.r8">[8]</xref>&#x000a0;CKD affects about 15% of the population in the U.S.<xref ref-type="bibr" rid="article-23202.r9">[9]</xref>&#x000a0;In chronic kidney disease (CKD),&#x000a0;increased PTH levels are seen, and there is a strong correlation between the prevalence and stage of CKD, with increasing prevalence seen&#x000a0;in advanced CKD.<xref ref-type="bibr" rid="article-23202.r7">[7]</xref></p>
      </sec>
      <sec id="article-23202.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Hypocalcemia is the most important stimulus for increased secretion of PTH from parathyroid glands in SHPT. The increased stimulation also results in parathyroid hyperplasia. Increased PTH level&#x000a0;results in increased calcium and phosphate absorption from the gut. PTH acts as a stimulus for increased osteoclast activity, which results in calcium and phosphorus resorption from the bone.<xref ref-type="bibr" rid="article-23202.r6">[6]</xref>&#x000a0;PTH activates vitamin D in the kidneys to its active form. Vitamin D increases calcium and phosphorus absorption from the gut and calcium and phosphorus reabsorption in renal tubules.<xref ref-type="bibr" rid="article-23202.r6">[6]</xref>. Also, vitamin D suppresses PTH secretion from parathyroid glands and regulates the calcium and phosphorus levels.<xref ref-type="bibr" rid="article-23202.r6">[6]</xref></p>
        <p>Fibroblast growth factor 23 (FGF-23) is secreted by osteocytes and plays an important role in phosphorus homeostasis by increasing phosphorus clearance in the renal tubules.<xref ref-type="bibr" rid="article-23202.r6">[6]</xref>&#x000a0;FGF-23 also inhibits 1, alpha-hydroxylase activity, and thus the active form of vitamin D.<xref ref-type="bibr" rid="article-23202.r6">[6]</xref>&#x000a0;FGF-23 is not known to modulate PTH secretion directly but may do so indirectly through regulating phosphate and vitamin D metabolism.<xref ref-type="bibr" rid="article-23202.r10">[10]</xref></p>
        <p>In&#x000a0;chronic kidney disease, decreasing glomerular filtration rate (GFR) leads to increased secretion of PTH. Decreasing GFR leads to decreased phosphate clearance and hyperphosphatemia, which then stimulates the parathyroid glands to secrete PTH.<xref ref-type="bibr" rid="article-23202.r11">[11]</xref>&#x000a0;Also, hyperphosphatemia causes hypocalcemia (phosphorus forms complexes with calcium)&#x000a0;and stimulates FGF-23 and increased PTH secretion.<xref ref-type="bibr" rid="article-23202.r11">[11]</xref></p>
      </sec>
      <sec id="article-23202.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In&#x000a0;chronic renal failure, there is an increase in the ability of parathyroid cells to synthesize and secrete hormone, which is responsible for an increase in serum PTH concentration at first. This results in hyperplasia of the gland linked to both cell hypertrophy and increased cell proliferation, which is still potentially inhibited by therapeutic measures. As renal function deteriorates, the expression of calcium, vitamin D, and FGF23 receptors gradually decreases in the parathyroid gland, which leads to parathyroid gland hyperplasia.<xref ref-type="bibr" rid="article-23202.r12">[12]</xref>&#x000a0;Clones appear as nodular hyperplasia, which gives rise to true autonomic adenomas, thus causing&#x000a0;tertiary hyperparathyroidism.<xref ref-type="bibr" rid="article-23202.r13">[13]</xref></p>
        <p>Parathyroid hyperplasia is classified into four categories: diffuse hyperplasia, diffuse and multinodular hyperplasia, multinodular hyperplasia, and the simple nodular hyperplasia.<xref ref-type="bibr" rid="article-23202.r14">[14]</xref><xref ref-type="bibr" rid="article-23202.r15">[15]</xref></p>
        <p>Renal osteodystrophy&#x000a0;comprises&#x000a0;a group of bone mineral disorders. There are five types based on histological classification.<xref ref-type="bibr" rid="article-23202.r16">[16]</xref></p>
        <p>Mild disease is a state of slightly increased bone remodeling and usually seen in early or treated SHPT.<xref ref-type="bibr" rid="article-23202.r16">[16]</xref></p>
        <p>Osteitis fibrosa cystica is a state of high bone turnover from increased osteoclast activity and bone destruction and resorption caused by the high PTH levels.<xref ref-type="bibr" rid="article-23202.r11">[11]</xref>&#x000a0;It is characterized by peritrabecular fibrosis.<xref ref-type="bibr" rid="article-23202.r16">[16]</xref></p>
        <p>Osteomalacia is the softening of the bone due to inadequate osteoid or insufficient mineralization of the osteoid, depending upon the rate of bone remodeling. The problems with mineralization arise due to abnormal calcium and phosphorus metabolism.<xref ref-type="bibr" rid="article-23202.r17">[17]</xref></p>
        <p>Mixed disease has features of both osteomalacia and osteitis fibrosa and is associated with aluminum deposition&#x000a0;<xref ref-type="bibr" rid="article-23202.r16">[16]</xref>.</p>
        <p>Administration and overuse of vitamin D analogs, calcimimetics, and phosphate binders decrease PTH levels, which, in turn, leads to a state of low bone turnover with normal mineralization known as adynamic bone disease.<xref ref-type="bibr" rid="article-23202.r11">[11]</xref></p>
      </sec>
      <sec id="article-23202.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In SHPT, the disorder of phosphocalcic metabolism will affect the different systems of the body and manifests&#x000a0;by specific clinical signs. Primarily bone, and then soft tissues are affected. Skin can also be affected.</p>
        <p>In SHPT, bone remodeling and mineralization are affected.<xref ref-type="bibr" rid="article-23202.r17">[17]</xref>&#x000a0;Bony skeletal deformities are secondary to bone remodeling.<xref ref-type="bibr" rid="article-23202.r17">[17]</xref>&#x000a0;This leads to bone deformation, bone pain, and bone fractures in extreme cases. Chest wall deformity&#x000a0;and kyphoscoliosis can be noted due to abnormal mineralization and bone remodeling.<xref ref-type="bibr" rid="article-23202.r18">[18]</xref>&#x000a0;Pelvic bones, hip joints, and bones of lower extremities can be deformed, and increased stress from weight-bearing can lead to fractures.<xref ref-type="bibr" rid="article-23202.r18">[18]</xref>&#x000a0;In children, bone deformities in SHPT&#x000a0;can lead&#x000a0;to rickets.<xref ref-type="bibr" rid="article-23202.r19">[19]</xref></p>
        <p>Extraosseous manifestations are also seen. Calcifications affect the arterial walls, viscera, periarticular tissue, cutaneous tissue, and the eye (cornea and conjunctiva). They are thus responsible for muscle weakness, red-eye syndrome, and intense pruritus.<xref ref-type="bibr" rid="article-23202.r17">[17]</xref>&#x000a0;Pruritis is especially seen in advanced renal disease and is due to the deposition of calcium and phosphorus on the skin. Calcifications can occur in the heart, myocardium, aortic, and mitral valves and can lead to increased cardiovascular events such as ischemia, left ventricular dysfunction, congestive heart failure, arrhythmias, and death.<xref ref-type="bibr" rid="article-23202.r20">[20]</xref><xref ref-type="bibr" rid="article-23202.r21">[21]</xref></p>
        <p>Calciphylaxis can be seen as ulceration of the skin, resulting from arterial obstruction, with cutaneous necrosis of the extremities.<xref ref-type="bibr" rid="article-23202.r17">[17]</xref>&#x000a0;Calciphylaxis is caused by high levels of PTH, calcium, and phosphorus induced by high levels of calcium in dialysate and phosphate binders.<xref ref-type="bibr" rid="article-23202.r18">[18]</xref>&#x000a0;In calciphylaxis, there is calcification of small arterioles and venules with severe intimal hyperplasia and can be complicated by thrombosis leading to painful skin necrosis.<xref ref-type="bibr" rid="article-23202.r18">[18]</xref>&#x000a0;Increased risk of infections, sepsis, and ischemia contributes to increased mortality risk in calciphylaxis.<xref ref-type="bibr" rid="article-23202.r18">[18]</xref></p>
        <p>Other manifestations in SHPT&#x000a0;include psychological and neurological problems,&#x000a0;as well as&#x000a0;malnutrition.<xref ref-type="bibr" rid="article-23202.r22">[22]</xref></p>
      </sec>
      <sec id="article-23202.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation in SHPT consists of&#x000a0;monitoring&#x000a0;the lab values of PTH, calcium, phosphorus, vitamin D levels, and renal function.</p>
        <p>Since it can present as bone mineral disorder and affect the musculoskeletal system,&#x000a0;Kidney Disease for Improving Global Outcomes (KDIGO) 2017 recommends systematically performing bone mineral density in dialysis patients with bone mineralization disorders to assess the risk of pathological fracture.<xref ref-type="bibr" rid="article-23202.r23">[23]</xref></p>
        <p>There are certain striking radiological features in renal osteodystrophy. Osteosclerosis is increased bone density, especially in the axial skeleton, but bone is structurally weak and prone to&#x000a0;stress fractures.<xref ref-type="bibr" rid="article-23202.r24">[24]</xref>&#x000a0;"Rugger jersey" spine sign is a hallmark sign of osteosclerosis in SHPT.<xref ref-type="bibr" rid="article-23202.r25">[25]</xref>&#x000a0;Osteomalacia is softening of the bone due to poor mineralization of the newly formed osteoid and is characterized by the presence of looser zones on imaging.<xref ref-type="bibr" rid="article-23202.r24">[24]</xref>&#x000a0;</p>
        <p>The brown tumor in SHPT&#x000a0;is a lytic&#x000a0;bone lesion caused by increased osteoclastic activity and proliferation of fibroblasts.<xref ref-type="bibr" rid="article-23202.r26">[26]</xref>&#x000a0;On a standard radiograph, it presents itself as a well defined hypodense lesion. These tumors are located more commonly in hands, feet, facial bones, and skull.<xref ref-type="bibr" rid="article-23202.r26">[26]</xref>&#x000a0;Brown tumor represents the terminal stage of bone mineral disorder in secondary hyperparathyroidism.<xref ref-type="bibr" rid="article-23202.r27">[27]</xref>&#x000a0;Brown tumors can be misdiagnosed as neoplasms on imaging.<xref ref-type="bibr" rid="article-23202.r27">[27]</xref></p>
        <p>Osteitis fibrosa cystica&#x000a0;is revealed on standard radiographs by subperiosteal resorption, especially at&#x000a0;the distal&#x000a0;phalanges, clavicles, distal ulna, and skull.<xref ref-type="bibr" rid="article-23202.r25">[25]</xref>&#x000a0;Cortical thinning in&#x000a0;long bones, bone cysts, and densification of the trabecular bone are also seen.<xref ref-type="bibr" rid="article-23202.r25">[25]</xref></p>
        <p>Periarticular, vascular, and more rarely, visceral metastatic calcifications can also be found.<xref ref-type="bibr" rid="article-23202.r17">[17]</xref>&#x000a0;There are no clear guidelines regarding lab or diagnostic testing for vascular calcifications in SHPT.<xref ref-type="bibr" rid="article-23202.r28">[28]</xref></p>
      </sec>
      <sec id="article-23202.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Medical Treatment</bold>
</p>
        <p>Management&#x000a0;of SHPT targets abnormal phosphocalcic metabolism. Maintaining the serum calcium and phosphorus levels within the normal range along with control of PTH and vitamin D levels&#x000a0;is the key in&#x000a0;management&#x000a0;of secondary hyperparathyroidism. The U.S. National Kidney Foundation (NKF) proposed the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines and established targets for biomarkers (calcium, phosphorus, and PTH levels) to lower SHPT&#x000a0;related mortality.<xref ref-type="bibr" rid="article-23202.r29">[29]</xref>&#x000a0;Also, the Kidney Disease Improving Global Outcomes (KDOGI) proposed clinical practice guidelines to address the management of CKD-MBD in dialysis patients.<xref ref-type="bibr" rid="article-23202.r29">[29]</xref>&#x000a0;However, most of these targets are difficult to achieve in the long term.</p>
        <p>Phosphate binders, vitamin D, and calcimimetics&#x000a0;have been reported in the management&#x000a0;of calcium and phosphate levels in patients with CKD. In addition, patients are advised to restrict dietary intake of phosphorus&#x000a0;by limiting phosphate-rich foods such as soda&#x000a0;beverages, meat, cheese, and dietary products.<xref ref-type="bibr" rid="article-23202.r6">[6]</xref>&#x000a0;</p>
        <p>Phosphate binders include aluminum hydroxide, sevelamer hydrochloride, sevelamer carbonate, and lanthanum carbonate.<xref ref-type="bibr" rid="article-23202.r6">[6]</xref>&#x000a0;Phosphate binders can be calcium-containing or calcium-free. Calcium-containing phosphate binders are known to increase vascular and soft tissue calcification and are associated with lower survival as compared to calcium-free phosphate binders.<xref ref-type="bibr" rid="article-23202.r30">[30]</xref></p>
        <p>Vitamin D metabolites include cholecalciferol (vitamin D3) and ergocalciferol, which is vitamin D2. Vitamin D analogs such as calcitriol, paricalcitol, alfacalcidol, and doxercalciferol are grouped under vitamin D receptor activators (VDRA) based on their site of action. Vitamin D could have a possible survival benefit in CKD patients.<xref ref-type="bibr" rid="article-23202.r31">[31]</xref>&#x000a0;Vitamin D analogs' use in CKD has been shown to decrease PTH levels and they are likely associated with reduced inflammation, decreased tubulointerstitial fibrosis, improved endothelial function, inhibition of renin-angiotensin system, prevention of vascular calcification and decreased cardiovascular outcomes, reduced hospitalizations, and improved mortality.<xref ref-type="bibr" rid="article-23202.r31">[31]</xref>&#x000a0;However, the&#x000a0;majority of these findings is from observational studies, and randomized control studies are needed to validate the outcomes.<xref ref-type="bibr" rid="article-23202.r31">[31]</xref></p>
        <p>Calcimimetics are agents that increase the sensitivity of calcium-sensing receptors (CaSR) in the parathyroid gland and lead to decreased PTH production. Cinacalcet is a calcimimetic drug&#x000a0;that is commercially available and extensively used in dialysis patients. Etelcalcitide is another calcimimetic. Important side effects of calcimimetics&#x000a0;include nausea,&#x000a0;hypocalcemia, QT prolongation, arrhythmias, worsening heart failure, and convulsions.<xref ref-type="bibr" rid="article-23202.r6">[6]</xref><xref ref-type="bibr" rid="article-23202.r32">[32]</xref>&#x000a0;Calcimimetics have been shown to suppress PTH levels but do not increase calcium or phosphorus levels.<xref ref-type="bibr" rid="article-23202.r31">[31]</xref>&#x000a0;Cinacalcet, along with low dose vitamin D, minimizes the risk of calcification while offering the benefits of PTH lowering therapy.<xref ref-type="bibr" rid="article-23202.r33">[33]</xref>&#x000a0;In Evaluation of Cinacalcet Therapy to Lower Cardiovascular Outcomes (EVOLVE) study, Cinacalcet did not improve survival or cardiovascular outcomes in dialysis patients but offered significant benefits in terms of lowering PTH, calcium, phosphate, and FGF-23 levels.<xref ref-type="bibr" rid="article-23202.r32">[32]</xref>&#x000a0;More RCT studies are needed to explore the full range of benefits of calcimimetics.</p>
        <p>
<bold>Surgical Treatment</bold>
</p>
        <p>Parathyroidectomy is a surgical modality available if medical therapy is unsuccessful or refractory. Other indications include calciphylaxis, refractory pruritus, severe hypercalcemia (serum calcium greater than 10.2 mg/dL) or hyperphosphatemia (serum phosphorus greater than 5.5 mg/dL), anemia hyporesponsive to erythropoietin, PTH levels more than 800 pg/mL (for more than 6 months despite medical therapy) and extraskeletal calcification.<xref ref-type="bibr" rid="article-23202.r6">[6]</xref><xref ref-type="bibr" rid="article-23202.r34">[34]</xref>&#x000a0;The parathyroid glands in secondary hyperparathyroidism are characterized by asymmetric enlargement and nodular hyperplasia. Assessment of parathyroid mass is an important factor in predicting the response to medical management. Glands&#x000a0;larger than 1 cm in size or greater than 500 mm^3 ) on ultrasound represent glandular hyperplasia and are usually refractory to medical treatment.<xref ref-type="bibr" rid="article-23202.r34">[34]</xref>&#x000a0;It is estimated that surgery will be required in about 15% of patients in 10 years and 38% of patients in 20 years after the initiation of dialysis.<xref ref-type="bibr" rid="article-23202.r35">[35]</xref>&#x000a0;Following the introduction of calcimimetics, there appears to have been a reduction in parathyroidectomy rates.<xref ref-type="bibr" rid="article-23202.r34">[34]</xref>&#x000a0;</p>
        <p>Surgical techniques include subtotal parathyroidectomy and total parathyroidectomy with or without autotransplantation.<xref ref-type="bibr" rid="article-23202.r36">[36]</xref>&#x000a0;Subtotal parathyroidectomy involves leaving a remnant part of the gland while total parathyroidectomy removes all the glandular tissue. Sometimes, in total parathyroidectomy, small amounts of the parathyroid gland could be autografted post-surgery. There are no major differences between subtotal parathyroidectomy and total parathyroidectomy in outcomes such as complications, readmissions, 30-day mortality.<xref ref-type="bibr" rid="article-23202.r37">[37]</xref>&#x000a0;However, subtotal parathyroidectomy has been associated with lower extended hospital stay post-surgery and a lower incidence of postoperative hypocalcemia.<xref ref-type="bibr" rid="article-23202.r38">[38]</xref>&#x000a0;Subtotal parathyroidectomy is preferred in renal transplant patients with tertiary hyperparathyroidism due to a lower risk of recurrence.<xref ref-type="bibr" rid="article-23202.r39">[39]</xref>&#x000a0;Total parathyroidectomy without autotransplantation is associated with a lower rate of recurrence of refractory SHPT and is preferred in patients with longer life expectancy or less likelihood of renal transplantation.<xref ref-type="bibr" rid="article-23202.r40">[40]</xref>&#x000a0;Total parathyroidectomy with autotransplantation is preferred for patients who cannot undergo repeat neck surgeries due to conditions such as co-existing thyroid disorders requiring surgery, history of repeated neck surgeries, recurrent laryngeal nerve injury or patients with significant perioperative comorbidities.<xref ref-type="bibr" rid="article-23202.r34">[34]</xref></p>
        <p>An interesting postoperative complication of surgery is the hungry bone syndrome where the lack of osteoclastic activity causes decreased PTH, leading to hypocalcemia.<xref ref-type="bibr" rid="article-23202.r6">[6]</xref>&#x000a0;It can be prevented by administering high doses of calcium and using a high calcium dialysate post-surgery.<xref ref-type="bibr" rid="article-23202.r34">[34]</xref></p>
      </sec>
      <sec id="article-23202.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Primary and tertiary hyperparathyroidism&#x000a0;are always in the differential of secondary hyperparathyroidism. In primary hyperparathyroidism, there is increased secretion of PTH, which leads to increased calcium and phosphate levels.<xref ref-type="bibr" rid="article-23202.r41">[41]</xref>&#x000a0;In secondary hyperparathyroidism, there is hypocalcemia and hyperphosphatemia, which leads to increased PTH levels.<xref ref-type="bibr" rid="article-23202.r11">[11]</xref>&#x000a0; In tertiary hyperparathyroidism, the PTH levels are excessively high, and the calcium and phosphorus levels are high as well.<xref ref-type="bibr" rid="article-23202.r11">[11]</xref></p>
      </sec>
      <sec id="article-23202.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>In patients on hemodialysis, Dialysis Outcomes and Practice Patterns Study (DOPPS) has shown increased cardiovascular and all-cause mortality&#x000a0;with calcium level greater than 10 mg/dL, phosphorus level greater than 7 mg/dL, and PTH level greater than 600 pg/ml.<xref ref-type="bibr" rid="article-23202.r42">[42]</xref>&#x000a0;</p>
        <p>Evaluation of Cinacalcet Therapy to Lower Cardiovascular Outcomes (EVOLVE) study is the largest, double-blinded, placebo-controlled clinical trial conducted in dialysis patients with SHPT. This study showed that cinacalcet therapy did not offer survival benefit or improve cardiovascular outcomes in patients on hemodialysis.<xref ref-type="bibr" rid="article-23202.r43">[43]</xref></p>
        <p>In the ADVANCE study, cinacalcet with low dose vitamin D analogs as compared to flexible vitamin D dosing showed a positive trend in decreasing vascular calcification, although the study was inconclusive.<xref ref-type="bibr" rid="article-23202.r32">[32]</xref>&#x000a0;</p>
        <p>OPTIMA study is a multicenter, open-label study that&#x000a0;looked into&#x000a0;cinacalcet based treatment algorithms&#x000a0;being compared with conventional therapy in dialysis patients showed an increase in the achievement of KDOQI targets.<xref ref-type="bibr" rid="article-23202.r44">[44]</xref></p>
        <p>Observational studies have shown that parathyroidectomy is beneficial in dialysis patients as it can lead to normalization of calcium and phosphorus, reduced fracture rate, improved health-related quality of life, and decreased all-cause mortality.<xref ref-type="bibr" rid="article-23202.r34">[34]</xref>&#x000a0;However, randomized controlled trials are lacking to validate these benefits. More prospective trials are needed to look at the outcomes of&#x000a0;calcimimetics and parathyroidectomy.</p>
      </sec>
      <sec id="article-23202.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Secondary hyperparathyroidism can have a significant impact on life due to complications such as bone and mineral disorders, cardiovascular complications, and calciphylaxis. Quality of life can be affected by symptoms such as muscle pain, bone pain, and fractures in extreme cases. Although medical therapy has been aimed to achieve target levels per Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, there is not much clinical evidence from prospective studies suggesting an improvement in survival due to vitamin D analogs or calcimimetics.<xref ref-type="bibr" rid="article-23202.r45">[45]</xref>&#x000a0;Calcimimetics have been shown to improve certain outcomes such as improvement in rates of parathyroidectomy, fractures, cardiovascular hospitalizations, and certain health-related quality of life parameters.<xref ref-type="bibr" rid="article-23202.r45">[45]</xref>&#x000a0;Parathyroidectomy is indicated in medically refractory disease. In ESRD patients on hemodialysis, the incidence of parathyroidectomy goes up with time, with about 15% of these patients undergoing surgery in 5 to 10 years from initiation of dialysis.<xref ref-type="bibr" rid="article-23202.r34">[34]</xref>&#x000a0;A study showed that parathyroidectomy, regardless of the technique used, significantly relieved most of the initial functional signs within seven days of the procedure, but patients continued to experience mild to moderate symptoms over a six-month follow-up.<xref ref-type="bibr" rid="article-23202.r46">[46]</xref>&#x000a0;Surgery and calcimimetics can offer improved survival in the initial stages of CKD resistance to standard therapy.<xref ref-type="bibr" rid="article-23202.r47">[47]</xref>&#x000a0;Surgery has not been shown to&#x000a0;offer improved cardiovascular morbidity or mortality benefit in secondary hyperparathyroidism patients on hemodialysis.<xref ref-type="bibr" rid="article-23202.r47">[47]</xref></p>
      </sec>
      <sec id="article-23202.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Secondary hyperparathyroidism is common among patients with vitamin D deficiency and chronic kidney disease. Since about half of&#x000a0;the world population is vitamin D deficient, and about 1/7 have CKD, it is important to understand the condition in depth. Calcium, phosphorus, and vitamin D metabolism&#x000a0;are affected in secondary hyperparathyroidism. This leads to several bone-mineralization disorders, renal osteodystrophy, and calcifications in extraosseous sites, including coronary calcifications that can lead to devastating cardiovascular outcomes and increased mortality. Thus, it is important to detect this disorder early and start therapy. Medical treatments include vitamin D analogs, calcimimetics, and phosphate binders to restore calcium, phosphorus, and the&#x000a0;PTH levels within normal range. Early consultation with nephrologists is important to manage the outcomes. Surgery is the last option if patients do not respond to appropriate medical treatments.</p>
      </sec>
      <sec id="article-23202.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23202&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23202">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/secondary-hyperparathyroidism/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23202">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23202/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23202">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23202.s15">
        <title>References</title>
        <ref id="article-23202.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potts</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Chemistry and physiology of parathyroid hormone.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>1976</year>
            <volume>5 Suppl</volume>
            <fpage>307S</fpage>
            <page-range>307S-315S</page-range>
            <pub-id pub-id-type="pmid">802686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silver</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease.</article-title>
            <source>Kidney Int Suppl</source>
            <year>2005</year>
            <month>Jun</month>
            <issue>95</issue>
            <fpage>S8</fpage>
            <page-range>S8-12</page-range>
            <pub-id pub-id-type="pmid">15882315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isakova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nickolas</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Denburg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yarlagadda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rosas</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Nigwekar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and&#x000a0;Treatment of Chronic Kidney Disease-Mineral and Bone&#x000a0;Disorder (CKD-MBD).</article-title>
            <source>Am J Kidney Dis</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>737</fpage>
            <page-range>737-751</page-range>
            <pub-id pub-id-type="pmid">28941764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stehman-Breen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Muirhead</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thorning</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sherrard</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Secondary hyperparathyroidism complicated by parathyromatosis.</article-title>
            <source>Am J Kidney Dis</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>502</fpage>
            <page-range>502-7</page-range>
            <pub-id pub-id-type="pmid">8840938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lorenz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bartsch</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Sancho</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Guigard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Triponez</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Surgical management of secondary hyperparathyroidism in chronic kidney disease--a consensus report of the European Society of Endocrine Surgeons.</article-title>
            <source>Langenbecks Arch Surg</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>400</volume>
            <issue>8</issue>
            <fpage>907</fpage>
            <page-range>907-27</page-range>
            <pub-id pub-id-type="pmid">26429790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saliba</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>El-Haddad</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Secondary hyperparathyroidism: pathophysiology and treatment.</article-title>
            <source>J Am Board Fam Med</source>
            <year>2009</year>
            <season>Sep-Oct</season>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>574</fpage>
            <page-range>574-81</page-range>
            <pub-id pub-id-type="pmid">19734404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Plas</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Noltes</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>van Ginhoven</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Kruijff</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Secondary and Tertiary Hyperparathyroidism: A Narrative Review.</article-title>
            <source>Scand J Surg</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>109</volume>
            <issue>4</issue>
            <fpage>271</fpage>
            <page-range>271-278</page-range>
            <pub-id pub-id-type="pmid">31364494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouillon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Lips</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Vitamin D deficiency.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Nov</month>
            <day>08</day>
            <volume>357</volume>
            <issue>19</issue>
            <fpage>1980</fpage>
            <page-range>1980-1; author reply 1981-2</page-range>
            <pub-id pub-id-type="pmid">17989396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horowitz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Miskulin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zager</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of hypertension in CKD.</article-title>
            <source>Adv Chronic Kidney Dis</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>88</fpage>
            <page-range>88-95</page-range>
            <pub-id pub-id-type="pmid">25704344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krajisnik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rklund</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marsell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ljunggren</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Akerstr&#x000f6;m</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jonsson</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Westin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells.</article-title>
            <source>J Endocrinol</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>195</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-31</page-range>
            <pub-id pub-id-type="pmid">17911404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuen</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Ananthakrishnan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Hyperparathyroidism of Renal Disease.</article-title>
            <source>Perm J</source>
            <year>2016</year>
            <season>Summer</season>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>15</fpage>
            <page-range>15-127</page-range>
            <pub-id pub-id-type="pmid">27479950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dr&#x000fc;eke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Olgaard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sprague</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lameire</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Eknoyan</surname>
                <given-names>G</given-names>
              </name>
              <collab>Kidney Disease: Improving Global Outcomes (KDIGO)</collab>
            </person-group>
            <article-title>Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).</article-title>
            <source>Kidney Int</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>69</volume>
            <issue>11</issue>
            <fpage>1945</fpage>
            <page-range>1945-53</page-range>
            <pub-id pub-id-type="pmid">16641930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jamal</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Secondary and tertiary hyperparathyroidism.</article-title>
            <source>J Clin Densitom</source>
            <year>2013</year>
            <season>Jan-Mar</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-8</page-range>
            <pub-id pub-id-type="pmid">23267748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guillem</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vlaeminck-Guillem</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dracon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Noel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cussac</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Huglo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Proye</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Are preoperative examinations useful in the management of patients with renal hyperparathyroidism?].</article-title>
            <source>Ann Chir</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-33</page-range>
            <pub-id pub-id-type="pmid">16375845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Surgical management of secondary hyperparathyroidism: how to effectively reduce recurrence at the time of primary surgery.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2016</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>509</fpage>
            <page-range>509-14</page-range>
            <pub-id pub-id-type="pmid">26620950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hruska</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Teitelbaum</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Renal osteodystrophy.</article-title>
            <source>N Engl J Med</source>
            <year>1995</year>
            <month>Jul</month>
            <day>20</day>
            <volume>333</volume>
            <issue>3</issue>
            <fpage>166</fpage>
            <page-range>166-74</page-range>
            <pub-id pub-id-type="pmid">7791820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oprisiu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hottelart</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ghitsu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Said</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Westeel</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Morini&#x000e8;re</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>el Esper</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pruna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Renal osteodystrophy (1): invasive and non-invasive diagnosis of its pathologic varieties].</article-title>
            <source>Nephrologie</source>
            <year>2000</year>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>229</fpage>
            <page-range>229-37</page-range>
            <pub-id pub-id-type="pmid">11068772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Kishawi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>El-Nahas</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Renal osteodystrophy: review of the disease and its treatment.</article-title>
            <source>Saudi J Kidney Dis Transpl</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>373</fpage>
            <page-range>373-82</page-range>
            <pub-id pub-id-type="pmid">16970258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>JANCAR</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>RICKETS WITH SECONDARY HYPERPARATHYROIDISM IN A SEVERELY SUBNORMAL CHILD.</article-title>
            <source>Arch Dis Child</source>
            <year>1963</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>200</issue>
            <fpage>412</fpage>
            <page-range>412-4</page-range>
            <pub-id pub-id-type="pmid">14058816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkieson</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Gangji</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Voss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ingram</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ranganath</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Goldsmith</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Kotsamanes</surname>
                <given-names>CZ</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rabbat</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Clase</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Coronary artery calcification, cardiovascular events, and death: a prospective cohort study of incident patients on hemodialysis.</article-title>
            <source>Can J Kidney Health Dis</source>
            <year>2015</year>
            <volume>2</volume>
            <fpage>29</fpage>
            <pub-id pub-id-type="pmid">26269747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Llach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Overview of renal bone disease: causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach.</article-title>
            <source>Kidney Int Suppl</source>
            <year>2003</year>
            <month>Nov</month>
            <issue>87</issue>
            <fpage>S113</fpage>
            <page-range>S113-9</page-range>
            <pub-id pub-id-type="pmid">14531783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fraser</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Hyperparathyroidism.</article-title>
            <source>Lancet</source>
            <year>2009</year>
            <month>Jul</month>
            <day>11</day>
            <volume>374</volume>
            <issue>9684</issue>
            <fpage>145</fpage>
            <page-range>145-58</page-range>
            <pub-id pub-id-type="pmid">19595349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <collab>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group</collab>
            <article-title>KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone&#x000a0;Disorder (CKD-MBD).</article-title>
            <source>Kidney Int Suppl (2011)</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-59</page-range>
            <pub-id pub-id-type="pmid">30675420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Handa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kattapuram</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Imaging Findings of Metabolic Bone Disease.</article-title>
            <source>Radiographics</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1871</fpage>
            <page-range>1871-1887</page-range>
            <pub-id pub-id-type="pmid">27726750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacativa</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Pimentel</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Patr&#x000ed;cio Filho</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Farias</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of radiological findings among cases of severe secondary hyperparathyroidism.</article-title>
            <source>Sao Paulo Med J</source>
            <year>2009</year>
            <month>May</month>
            <volume>127</volume>
            <issue>2</issue>
            <fpage>71</fpage>
            <page-range>71-7</page-range>
            <pub-id pub-id-type="pmid">19597681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Queiroz</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Queiroz</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Cruso&#x000e9;-Rebello</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Le&#x000e3;o</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Brown tumor of secondary hyperparathyroidism: surgical approach and clinical outcome.</article-title>
            <source>Oral Maxillofac Surg</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>435</fpage>
            <page-range>435-439</page-range>
            <pub-id pub-id-type="pmid">27640197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chew</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Huang-Hellinger</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Brown tumor.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>1993</year>
            <month>Apr</month>
            <volume>160</volume>
            <issue>4</issue>
            <fpage>752</fpage>
            <pub-id pub-id-type="pmid">8456657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Hewitson</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Tests for Vascular Calcification.</article-title>
            <source>Adv Chronic Kidney Dis</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>445</fpage>
            <page-range>445-463</page-range>
            <pub-id pub-id-type="pmid">31831123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cozzolino</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>CKD-MBD KDIGO guidelines: how difficult is reaching the 'target'?</article-title>
            <source>Clin Kidney J</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>70</fpage>
            <page-range>70-72</page-range>
            <pub-id pub-id-type="pmid">29423205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palmer</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tonelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mavridis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ruospo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Strippoli</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>691</fpage>
            <page-range>691-702</page-range>
            <pub-id pub-id-type="pmid">27461851</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gravellone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Martina</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mezzina</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Regalia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gallieni</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Vitamin d receptor activators and clinical outcomes in chronic kidney disease.</article-title>
            <source>Int J Nephrol</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>419524</fpage>
            <pub-id pub-id-type="pmid">21647319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cozzolino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galassi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Conte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mangano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Lullo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bellasi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2017</year>
            <volume>13</volume>
            <fpage>679</fpage>
            <page-range>679-689</page-range>
            <pub-id pub-id-type="pmid">28615947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Francisco</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Carrera</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A new paradigm for the treatment of secondary hyperparathyroidism.</article-title>
            <source>NDT Plus</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>1</volume>
            <issue>Suppl 1</issue>
            <fpage>i24</fpage>
            <page-range>i24-i28</page-range>
            <pub-id pub-id-type="pmid">25983953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lau</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Obi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kalantar-Zadeh</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Parathyroidectomy in the Management of Secondary Hyperparathyroidism.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2018</year>
            <month>Jun</month>
            <day>07</day>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>952</fpage>
            <page-range>952-961</page-range>
            <pub-id pub-id-type="pmid">29523679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Slater</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Karakas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bartsch</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Schlosser</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Initial parathyroid surgery in 606 patients with renal hyperparathyroidism.</article-title>
            <source>World J Surg</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>318</fpage>
            <page-range>318-26</page-range>
            <pub-id pub-id-type="pmid">22202993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veyrat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fessi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haymann</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ronco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lacau St Guily</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;ri&#x000e9;</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Conservative three-quarter versus subtotal seven-eighths parathyroidectomy in secondary hyperparathyroidism.</article-title>
            <source>Eur Ann Otorhinolaryngol Head Neck Dis</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>136</volume>
            <issue>2</issue>
            <fpage>63</fpage>
            <page-range>63-68</page-range>
            <pub-id pub-id-type="pmid">30327179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Total parathyroidectomy with autotransplantation versus subtotal parathyroidectomy for renal hyperparathyroidism: A systematic review and meta-analysis.</article-title>
            <source>Nephrology (Carlton)</source>
            <year>2017</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>388</fpage>
            <page-range>388-396</page-range>
            <pub-id pub-id-type="pmid">27085089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ruel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Youngwirth</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stang</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Scheri</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Roman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Subtotal vs. total parathyroidectomy with autotransplantation for patients with renal hyperparathyroidism have similar outcomes.</article-title>
            <source>Am J Surg</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>214</volume>
            <issue>5</issue>
            <fpage>914</fpage>
            <page-range>914-919</page-range>
            <pub-id pub-id-type="pmid">28736060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nichol</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Starling</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Klovning</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma.</article-title>
            <source>Ann Surg</source>
            <year>2002</year>
            <month>May</month>
            <volume>235</volume>
            <issue>5</issue>
            <fpage>673</fpage>
            <page-range>673-8; discussion 678-80</page-range>
            <pub-id pub-id-type="pmid">11981213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Zha</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>ZP</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Cen</surname>
                <given-names>XX</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>CX</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>To assess the effects of parathyroidectomy (TPTX versus TPTX+AT) for Secondary Hyperparathyroidism in chronic renal failure: A Systematic Review and Meta-Analysis.</article-title>
            <source>Int J Surg</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>44</volume>
            <fpage>353</fpage>
            <page-range>353-362</page-range>
            <pub-id pub-id-type="pmid">28634117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilezikian</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cusano</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bandeira</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Primary hyperparathyroidism.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2016</year>
            <month>May</month>
            <day>19</day>
            <volume>2</volume>
            <fpage>16033</fpage>
            <pub-id pub-id-type="pmid">27194212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tentori</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Blayney</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bommer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Akizawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Akiba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pisoni</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Port</surname>
                <given-names>FK</given-names>
              </name>
            </person-group>
            <article-title>Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).</article-title>
            <source>Am J Kidney Dis</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>519</fpage>
            <page-range>519-30</page-range>
            <pub-id pub-id-type="pmid">18514987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chertow</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pupim</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Block</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Correa-Rotter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Drueke</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Moe</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Albizem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Klassen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parfrey</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>5</issue>
            <fpage>898</fpage>
            <page-range>898-905</page-range>
            <pub-id pub-id-type="pmid">17702710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mac&#x000e1;rio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yaqoob</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bouman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>von Albertini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brink</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maduell</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Graf</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fraz&#x000e3;o</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bos</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Torregrosa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Saha</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reichel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wilkie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zani</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Molemans</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-45</page-range>
            <pub-id pub-id-type="pmid">18178780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shanahan</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Clinical outcomes in secondary hyperparathyroidism and the potential role of calcimimetics.</article-title>
            <source>NDT Plus</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>1</volume>
            <issue>Suppl 1</issue>
            <fpage>i29</fpage>
            <page-range>i29-i35</page-range>
            <pub-id pub-id-type="pmid">25983954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bratucu</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Garofil</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Radu</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Paic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goleanu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zurzu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Popa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Strambu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Straja</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Measurement of Quality of Life after Total Parathyroidectomy in Patients with Secondary Hyperparathyroidism and End Stage Renal Disease.</article-title>
            <source>Chirurgia (Bucur)</source>
            <year>2015</year>
            <season>Nov-Dec</season>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>511</fpage>
            <page-range>511-7</page-range>
            <pub-id pub-id-type="pmid">26713824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23202.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perna</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Savica</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Palazzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Della Pietra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ingrosso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Satta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Capasso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Docimo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era.</article-title>
            <source>BMC Surg</source>
            <year>2013</year>
            <volume>13 Suppl 2</volume>
            <issue>Suppl 2</issue>
            <fpage>S4</fpage>
            <pub-id pub-id-type="pmid">24268127</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
